基于新型Gd-IgA1抗体的超灵敏免疫分析及其在IgA肾病诊断中的应用
本研究开发了基于新型抗Gd-IgA1单克隆抗体MH33的时间分辨荧光免疫分析(TRFIA),用于检测Gd-IgA1。MH33识别与KM55不同的表位,该法检测限0.20 RU/ml,鉴别IgA肾病与对照的AUC为0.90,优于KM55的0.78。
要点
- MH33抗体识别不同于KM55的GalNAc修饰铰链区表位。
- MH33-TRFIA鉴别IgA肾病AUC 0.90,优于KM55的0.78。
- 最佳 cut-off 22.0 RU/ml时,特异性93.82%,敏感性64.44%。
核心结论
- 基于MH33的TRFIA为Gd-IgA1检测提供了敏感方法,对IgA肾病诊断表现出良好性能。
研究设计与样本
- 研究开发并评估了基于新型抗Gd-IgA1单克隆抗体MH33的TRFIA,并与基于KM55的 assay 进行比较。
- 评估对象包括健康对照、非IgA肾病肾脏病对照和IgA肾病患者。
主要发现
- SPR分析显示MH33识别GalNAc修饰的IgA1铰链区糖肽,表位不同于KM55。
- MH33-TRFIA检测限0.20 RU/ml,定量范围0.20-600 RU/ml,批内和批间变异系数分别为2.32%-5.49%和3.97%-5.23%,回收率89.80%-103.76%。
- 与KM55的相关性中等(IgA肾病,r=0.23,P=0.09)。
- 鉴别IgA肾病与联合对照的AUC为0.90(95%CI:0.86-0.93),KM55为0.78(95%CI:0.71-0.86)。
- 最佳 cut-off 22.0 RU/ml时,特异性93.82%,敏感性64.44%。
关键数值与推荐
- MH33-TRFIA检测限0.20 RU/ml,定量范围0.20-600 RU/ml。
- 鉴别IgA肾病与联合对照的AUC为0.90(95%CI:0.86-0.93)。
- 最佳 cut-off 22.0 RU/ml时,特异性93.82%,敏感性64.44%。
临床怎么用
- MH33-TRFIA可作为无创辅助诊断IgA肾病的血清学工具,但需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: IgA nephropathy (IgAN) diagnosis remains dependent on invasive renal biopsy because currently available serologic biomarkers, including galactose-deficient IgA1 (Gd-IgA1), have limited diagnostic performance. This study aimed to develop and evaluate a high-sensitivity time-resolved fluorescence immunoassay (TRFIA) based on a novel anti-Gd-IgA1 monoclonal antibody (i.e., MH33) for Gd-IgA1 detection in IgAN. METHODS: MH33 glycoepitope specificity was characterized using surface plasmon resonance (SPR). An MH33-based TRFIA was developed and evaluated for analytical and diagnostic performance in healthy controls (HCs), non-IgAN renal disease controls, and patients with IgAN, with comparison to a KM55-based assay. RESULTS: SPR analysis showed that MH33 recognized a GalNAc-modified IgA1 hinge-region glycopeptide distinct from the KM55 epitope. The MH33-based TRFIA achieved a detection limit of 0.20 response units (RU)/ml, a quantification range of 0.20 to 600 RU/ml, and acceptable analytical performance (intra-/inter-assay coefficients of variation: 2.32%-5.49% and 3.97%-5.23%; recoveries: 89.80%-103.76%). Correlation with KM55 was moderate (IgAN, r = 0.23, P = 0.09). For distinguishing IgAN from combined controls (HCs and non-IgAN renal diseases), the MH33-based TRFIA yielded an area under the curve (AUC) of 0.90 (95% confidence interval [CI]: 0.86-0.93), compared with 0.78 (95% CI: 0.71-0.86) for KM55. At the optimal cutoff value (22.0 RU/ml), the assay achieved a specificity of 93.82% and sensitivity of 64.44%. CONCLUSION: MH33-based TRFIA provides a sensitive approach for Gd-IgA1 detection and demonstrates favorable diagnostic performance for IgAN.
引用
- Kao S, Zhang Y, Dang S, et al. Ultrasensitive Immunoassay Using a Novel Galactose-Deficient IgA1 Antibody and Its Clinical Application in the Diagnosis of IgAN. Kidney Int Rep. 2026. PMID: 42394720. doi:10.1016/j.ekir.2026.106642
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。